Transcatheter Aortic Valve Implantation and Cardiac Conduction Abnormalities: Prevalence, Risk Factors and Management.
Michał Szotek, Łukasz Drużbicki, Karol Sabatowski...
https://pubmed.ncbi.nlm.nih.gov/37762995/Actively Recruiting
Led by Portuguese Association of Interventional Cardiology · Updated on 2026-10-14
500
Participants Needed
12
Research Sites
21 weeks
Total Duration
This registry study focuses on adults with severe, symptomatic aortic stenosis who require valve replacement. It aims to evaluate how the Medtronic Evolut FX transcatheter aortic valve implantation TAVI System performs in these patients. The study seeks to determine whether using a standardized procedure for implanting the valve can improve safety and efficiency, and it will look at patient outcomes both shortly after the procedure and up to one year later. Participants will undergo the TAVI procedure with the Medtronic Evolut FX system as part of their usual medical care. The study will follow their progress during the hospital stay, at 30 days, and at one year after the procedure. This follow-up will assess heart health, valve function, and recovery, collecting data on complications, the need for pacemakers, and other relevant clinical outcomes. People taking part will have their health monitored through hospital visits and evaluations at specific time points. The main outcome is technical success immediately after the valve implantation. Researchers will also measure several important health events such as pacemaker implantation rates, hospital stay length, mortality, stroke, bleeding, kidney injury, and valve function at 30 days and one year. The study plans to enroll 500 participants across 12 hospitals in Portugal, with monitoring continuing until study completion in April 2028.
CONDITIONS
PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI
R
Rui C Teles, MD, PhD
J
Joana D Silva, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Portuguese Association of Interventional Cardiology
Lead Sponsor
Medtronic
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
visit to confirm eligibility
Duration - Hospital stay duration
Participants undergo the transcatheter aortic valve implantation (TAVI) procedure with the Medtronic Evolut FX+ system as part of their routine care.
Hospital monitoring during stay
Duration - 1 year
Participants are monitored at 30 days and 1 year after the procedure to assess heart health, valve function, and recovery.
Visits or assessments at 30 days and 1 year
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Michał Szotek, Łukasz Drużbicki, Karol Sabatowski...
https://pubmed.ncbi.nlm.nih.gov/37762995/Vincent Auffret, Rishi Puri, Marina Urena...
https://pubmed.ncbi.nlm.nih.gov/28893961/Mohammad Hazique, Zubair Jafar, Sameer Lohana...
https://pubmed.ncbi.nlm.nih.gov/40582541/Kendra J Grubb, Hemal Gada, Douglas Fraser...
https://pubmed.ncbi.nlm.nih.gov/40454273/Susanne Jung, Markus Kondruweit, Mohamed Marwan...
https://pubmed.ncbi.nlm.nih.gov/40371597/Rui Campante Teles, Eric Van Belle, Radoslaw Parma...
https://pubmed.ncbi.nlm.nih.gov/39207816/Martin B Leon, Craig R Smith, Michael Mack...
https://pubmed.ncbi.nlm.nih.gov/20961243/Matteo Pagnesi, Won-Keun Kim, Sara Baggio...
https://pubmed.ncbi.nlm.nih.gov/37480891/Antonin Trimaille, Adrien Carmona, Sandy Hmadeh...
https://pubmed.ncbi.nlm.nih.gov/40530490/Mahmoud Abdelshafy, Ahmed Elkoumy, Hesham Elzomor...
https://pubmed.ncbi.nlm.nih.gov/37510950/Portuguese Association of Interventional Cardiology
Lead Sponsor
Medtronic
Collaborating Sponsor